Vamorolone

Active substance

Delta-1,4,9(11)-pregnatriene-17,21-dihydroxy-16-alpha-methyl-3,20-

dione

Holder

ReveraGen BioPharma

Status

Running

Indication

Duchenne Muscular Dystrophy in boys who are completing the VBP15-004 trial

Public documents

Approbation

Information for the patient

Informed consent

Last update

11/08/2022

Last updated on 28/09/2022